Publications by authors named "E Yazdani"

Introduction: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is revolutionizing the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) patients. This study aimed to establish patient-specific radiation dosimetry for [Lu]Lu-PSMA-617 RLT in Iranian patients with mCRPC.

Method: Twelve biopsy-proven prostate cancer patients (aged 68.

View Article and Find Full Text PDF

We report the third-order nonlinear optical (NLO) properties of ZnO@C-N composite microspheres and pure ZnO which have been investigated with the Z-scan technique under continuous wave laser. ZnO@C-N composite microspheres have been hydrothermally synthesized at two different precursor concentrations to have structures at different impurity levels. Moreover, pure ZnO is prepared under the annealing process.

View Article and Find Full Text PDF

Despite being time-consuming, SPECT/CT data is necessary for accurate dosimetry in patient-specific radiopharmaceutical therapy. We investigated how reducing the frame duration (FD) during SPECT acquisition can simplify the dosimetry workflow for [Lu]Lu-PSMA radioligand therapy (RLT). We aimed to determine the impact of shortened acquisition times on dosimetric precision.

View Article and Find Full Text PDF

Introduction: The inflammatory response to burn injuries can lead to organ dysfunction that ultimately results in increased mortality and morbidity. This meta-analysis was conducted to determine the efficacy of inflammatory biomarkers, including the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), procalcitonin (PCT), and C-reactive protein (CRP) as predictive tools of mortality among burn patients.

Material And Methods: The biomarker levels of survivors and non-survivors were consolidated according to guidelines for Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).

View Article and Find Full Text PDF

Background: Prostate-specific membrane antigen (PSMA) PET/CT imaging is widely used for quantitative image analysis, especially in radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). Unknown features influencing PSMA biodistribution can be explored by analyzing segmented organs at risk (OAR) and lesions. Manual segmentation is time-consuming and labor-intensive, so automated segmentation methods are desirable.

View Article and Find Full Text PDF